The extension provided by Nasdaq is a positive development for Entera Bio as it suggests that the company has more time to work on meeting the exchange's requirements without facing immediate delisting. This can be seen as a vote of confidence from Nasdaq and may alleviate immediate concerns from investors about the stock's listing status, potentially leading to a short-term positive impact on the stock price.